Results 251 to 260 of about 323,198 (362)

Visualisation of hypertension: A non-randomised pilot study to explore the feasibility of a Community Pharmacy-based intervention to support medication adherence (Hi-BP). [PDF]

PLoS One
Brown SL, McDonnell BJ, McRae D, Angel P, Khan I, Phillips R, Hallingberg B, James DH.   +7 more
europepmc   +1 more source

Do general practitioners and community pharmacists want information on the reasons for drug therapy changes implemented by secondary care?

, 1997
Angela Munday, B E Kelly, J. W. E. Forrester, Angela Timoney, E. M. McGovern   +4 more
openalex   +1 more source

Impact of a pharmacist-driven insulin dispensing program in a management services organization

Tina Benny, Marija Lapkus, Genevieve M Hale, Cynthia Moreau, Alexandra Pérez, Erika Zwachte   +5 more
openalex   +1 more source

Good Medicine: Why Pharmacists Should Be Prescribed a Right of Conscience [PDF]

, 2010
Duffy, Michael E.
core   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Developing a Pharmacist-Centered Novel Antimicrobial Stewardship (AMS) Approach for Healthcare in Pakistan: A Grounded Theory Study. [PDF]

Antibiotics (Basel)
Ali PA, Khan SE, Ahmad AMR.
europepmc   +1 more source

Exploring communication between pharmacists and infection control staff: a qualitative study in ministry of health hospitals, Riyadh, Saudi Arabia [PDF]

Abdullah Althemery, A. Alfaifi, Ali Alshehri, Nehad J. Ahmed, Saad Alaeena, Abdullah Aljahan   +5 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Quit bellyaching: the men and indigestion pilot study: executive summary [PDF]

, 2004
Hemingway, Ann, Taylor, G., Young, Natasha   +2 more
core  

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source